Pharmacological c-Jun NH2-Terminal Kinase (JNK) Pathway Inhibition Reduces Severity of Spinal Muscular Atrophy Disease in Mice by R. Schellino et al.
ORIGINAL RESEARCH
published: 04 September 2018
doi: 10.3389/fnmol.2018.00308
Pharmacological c-Jun NH2-Terminal
Kinase (JNK) Pathway Inhibition
Reduces Severity of Spinal Muscular
Atrophy Disease in Mice
Roberta Schellino1*†, Marina Boido1,2†, Tiziana Borsello3,4 and Alessandro Vercelli1,2
1Department of Neuroscience Rita Levi Montalcini, Neuroscience Institute Cavalieri Ottolenghi (NICO), University of Turin,
Turin, Italy, 2National Institute of Neuroscience (INN), Turin, Italy, 3Department of Pharmacological and Biomolecular Sciences,
University of Milan, Milan, Italy, 4Department of Neuroscience, IRCCS-Mario Negri Institute for Pharmacological Research,
Milan, Italy
Edited by:
Michele Papa,
Università degli Studi della Campania
“Luigi Vanvitelli” Caserta, Italy
Reviewed by:
Nicola Maggio,
Sheba Medical Center, Israel
Eduard Korkotian,
Weizmann Institute of Science, Israel
Andrea Beatriz Cragnolini,
Universidad Nacional de Cordoba,
Argentina
Andreas Vlachos,
Albert-Ludwigs-Universität Freiburg,
Germany
*Correspondence:
Roberta Schellino
roberta.schellino@gmail.com
†These authors have contributed
equally to this work
Received: 12 June 2018
Accepted: 14 August 2018
Published: 04 September 2018
Citation:
Schellino R, Boido M, Borsello T and
Vercelli A (2018) Pharmacological
c-Jun NH2-Terminal Kinase (JNK)
Pathway Inhibition Reduces Severity
of Spinal Muscular Atrophy Disease
in Mice.
Front. Mol. Neurosci. 11:308.
doi: 10.3389/fnmol.2018.00308
Spinal muscular atrophy (SMA) is a severe neurodegenerative disorder that occurs in
early childhood. The disease is caused by the deletion/mutation of the survival motor
neuron 1 (SMN1) gene resulting in progressive skeletal muscle atrophy and paralysis,
due to the degeneration of spinal motor neurons (MNs). Currently, the cellular and
molecular mechanisms underlying MN death are only partly known, although recently it
has been shown that the c-Jun NH2-terminal kinase (JNK)-signaling pathway might be
involved in the SMA pathogenesis. After confirming the activation of JNK in our SMA
mouse model (SMN2+/+; SMN∆7+/+; Smn−/−), we tested a specific JNK-inhibitor
peptide (D-JNKI1) on these mice, by chronic administration from postnatal day 1 to
10, and histologically analyzed the spinal cord and quadriceps muscle at age P12. We
observed that D-JNKI1 administration delayed MN death and decreased inflammation
in spinal cord. Moreover, the inhibition of JNK pathway improved the trophism of SMA
muscular fibers and the size of the neuromuscular junctions (NMJs), leading to an
ameliorated innervation of the muscles that resulted in improved motor performances
and hind-limb muscular tone. Finally, D-JNKI1 treatment slightly, but significantly
increased lifespan in SMA mice. Thus, our results identify JNK as a promising target
to reduce MN cell death and progressive skeletal muscle atrophy, providing insight into
the role of JNK-pathway for developing alternative pharmacological strategies for the
treatment of SMA.
Keywords: motor neuron disease, MAPK, motor endplates, therapy, innervation, muscle, motor performance,
apoptosis
INTRODUCTION
Spinal Muscular Atrophy (SMA) is a recessive autosomal neuromuscular disease that represents
the most common fatal pathology in infancy. The disease is caused by the mutation or deletion
of the survival motor neuron 1 (SMN1) gene, that leads to a progressive degeneration of spinal
motor neurons (MNs), resulting in the atrophy of the muscles of the limbs and trunk, and lastly
in death for respiratory complications (Lorson et al., 1999). Due to its defective splicing pattern,
the highly homologous copy gene SMN2 generates an insufficient amount of functional SMN
protein: therefore, the SMN2 copy number inversely correlates with the severity of SMA phenotype
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(Lorson et al., 2010), accounting for the presence of four main
clinical SMA types (SMA I-IV), characterized by different age of
onset and disease progression (Lefebvre et al., 1995).
Despite the genetic causes of SMA are well known, the
mechanisms underlying MN death are still poorly understood.
The low levels of SMN might probably lead to a selective
activation of intracellular stress signaling pathways in MNs,
initiating neurodegeneration (Burghes and Beattie, 2009;
Genabai et al., 2015).
Thus, investigating the molecular and cellular mechanisms
of cell death leading to MN degeneration could be extremely
relevant to prevent and/or delay the disease progression. Indeed,
although in the last years different translational approaches, both
SMN-dependent (e.g., RNA-based modulation of SMN2) and
SMN-independent (e.g., neurotrophic factors, stem cells), have
been adopted to develop therapeutics for SMA patients (Lorson
et al., 2010; Boido and Vercelli, 2016), the molecular pathways
involved in neurodegeneration remain unknown.
Recently, Genabai et al. (2015) reported that the c-Jun
NH2-terminal kinase (JNK) cascades ASK1/MKK4/7/JNK and
MEKK1/MKK4/7/JNK are activated in spinal cord of SMA mice
(SMN∆7) and patients (Genabai et al., 2015): in particular, an
increase in phosphorylation of the three JNK isoforms (JNK1,
2, 3) was visible in SMA phenotype and the brain-specific
isoform JNK isoform 3 (JNK3) mediated the neurodegeneration
caused by the low levels of SMN. By creating a double JNK3-
SMN∆7 knockout (KO) mouse model, the authors obtained a
milder SMA phenotype, demonstrating that JNK pathway might
represent a potential SMN-independent therapeutic target for the
treatment of SMA.
Based on these results, here we investigated the possibility
to impact on SMA progression by JNK inhibition: to this aim,
we administered to SMN∆7 mice (mouse model of intermediate
SMA) a cell-penetrating JNK inhibitor (D-JNKI1) peptide, which
selectively blocks the access of JNK to c-Jun and the other
JNK-binding domain (JBD) dependent targets. The structure of
the peptide and its competitive mechanism of inhibition have
been described by Borsello and colleagues in 2003 (Borsello
et al., 2003a). The neuroprotective efficacy of D-JNKI1 has been
already extensively proved, both in in vitro and in vivo studies:
its anti-apoptotic role was demonstrated in the treatment of
different brain pathological conditions and diseases, such as
cerebral ischemia (Borsello et al., 2003a; Repici et al., 2007),
neuropathic pain (Manassero et al., 2012), epilepsy (Spigolon
et al., 2010) and Alzheimer disease (Sclip et al., 2011, 2013,
2014).
By injecting D-JNKI1 in SMN∆7 pups, we expected to
counteract MN cell death, with the aim to reduce the progressive
neurodegeneration and atrophy occurring in SMA.
MATERIALS AND METHODS
Animals
SMN2+/+; SMN∆7+/+; SMN+/− mice (stock number 005025;
Jackson Lab, Bar Harbor, ME, USA) were bred to obtain the
experimental animals, i.e., SMN−/− (SMA, as model of type II
SMA) and SMN+/+ (WT) offspring. Pups were tail snipped at
postnatal day 0 (P0) for identification, and genotyped by PCR
assay (Valsecchi et al., 2015). SMA and WT pups were left in
the cage with the mother until the sacrifice at P12. Another
group of SMA mice were used for survival analysis. Animals had
free access to food and water, and were kept into regular cages
under 12/12-h light/dark cycle. All efforts weremade tominimize
the number of animals used and the suffering levels. Pups of
both sexes were used in this study. The experimental procedures
involving live animals were performed in strict accordance
to the European Communities Council Directive 86/609/EEC
(November 24, 1986) ItalianMinistry of Health and University of
Turin institutional guidelines on animal welfare (law 116/92 on
Care and Protection of living animals undergoing experimental
or other scientific procedures; permit number 17/2010-B, June
30, 2010). Additionally, the ad hoc Ethical Committee of the
University of Turin specifically approved this study. A total of
56 SMA and 29 WT mice were used.
D-JNKI1 Molecule and Peptide
Administration
The JNK-inhibitor is a cell-penetrating peptide that selectively
blocks the access of JNK to c-Jun and the other JBD-domain
substrates by a competitive mechanism, as described in
Borsello et al. (2003a). More in details, this inhibitor peptide
was obtained by linking the 10-amino acid HIV-TAT
sequence that directs cellular import to the 20-amino-acid
JNK-binding motif (JBD20) of JNK-interacting protein-1/islet-
brain 1 (JIP-1/IB1), which shows a similar binding motif
of c-Jun, but has a 100-fold higher affinity (Bonny et al.,
2001; Borsello et al., 2003a). WT and SMA animals were
divided into PBS- and D-JNKI1-treated groups. Treated
animals intraperitoneally received D-JNKI1 peptide diluted in
PBS (0.3 mg/kg; D-JNKI1 group; range of injected volume:
5–30 µl, depending on age and weight; Spigolon et al., 2010;
Manassero et al., 2012), while control mice received PBS.
D-JNKI1 peptide/PBS were injected every 3 days, starting
from P1.
Behavioral Assessment
Behavioral tests, specifically designed for neonatal rodents
(El-Khodor et al., 2008), were performed at different time
points: P2, P4, P7, P10, P12 on WT and SMA mice, of both
control (PBS treated) and D-JNKI1 treated groups (N = 3 WT
PBS; 22 SMA PBS; 11 WT D-JNKI1; 34 SMA D-JNKI1).
Animals were observed one at a time and then placed on a
heated pad (37◦C) until all the SMA and WT pups of the
litter had been tested. All pups were then mixed with the
cage bedding in order to minimize maternal rejection after
handling and then returned to their mother. Body weight
was measured before the tests, using a standard small animal
balance. Four behavioral tests were performed on pups following
protocols:
• Tail Suspension Test: in the tail suspension test pups were
suspended by the tail for 15 s and a score was assigned to their
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hind-limb posture, from 4 (normal hind-limb spread open) to
0 (hind-limb always closed together with clasping).
• Righting Reflex: pups were placed on their backs on a flat
surface and their failure or success in repositioning themselves
on dorsal side up was assessed over 30 s.
• Hind-limb suspension test: this test allowed to evaluate the
strength/weakness of the hind-limbs and the fatigue in pups.
They were placed head down, hanging by the hind-limbs in a
plastic 50 ml centrifuge tube with a cotton ball cushion at the
bottom for protection. The latency to fall from the edge of the
tube was evaluated and a score was assigned to the hind-limb
posture, as in the tail suspension test described above. The
test was performed in two consecutive trials and the average
latency and score were calculated.
• Negative Geotaxis: for the evaluation of motor coordination
and vestibular sensitivity, pups from P4 were placed on an
inclined surface (approximately 35◦ inclination) with the head
facing down. The ability of the pups to turn around and climb
upwards was evaluated within 60 s and recorded.
Tissue Preparation
For the histological analysis of the spinal cord, at P12 animals
(N = 3 WT PBS; 17 SMA PBS; 6 WT D-JNKI1; 29 SMA
D-JNKI1) were anesthetized by gaseous anesthesia and perfused
transcardially with phosphate buffer (0.1M PB, pH 7.4), followed
by cold 4% paraformaldehyde (PFA) in 0.1 M PB (pH 7.4).
The spinal cord was removed from the vertebral column at the
lumbar level (L1–L4) and postfixed in 4% PFA for 2 h. The tissue
was then cryoprotected in 30% sucrose solution in 0.1 M PB
buffer overnight, then embedded, and frozen in cryostat medium
(Killik, Bio-Optica, Milan, Italy). The spinal cord was cut into
transverse, 40 µm thick, free-floating sections that were stored
in an antifreeze solution (30% ethylene glycol, 30% glycerol, 10%
PB; 189 mM NaH2PO4; 192.5 mM NaOH; pH 7.4) and stored at
−20◦C until being used.
For the histological examination of quadriceps muscles,
another cohort of pups (five animals per group) were sacrificed
by cervical dislocation. Fresh quadriceps muscles were rapidly
collected, embedded in cryostat medium and cut on the cryostat.
Coronal and parasagittal muscle slices (20 µm thick) were cut
and collected directly onto 4% gelatin-coated glasses.
Immunohistochemistry
For immunofluorescence staining, after rinsing in PBS to remove
the antifreeze solution, the sections were incubated in a mixture
of primary antibodies diluted in 0.1 M PBS, pH 7.4, 0.5% Triton
X-100, and appropriate 2% normal sera for 24 h at 4◦C. The
following primary antibodies were used: anti-glial fibrillary acidic
protein (anti-GFAP; rabbit, DAKO Cytomation, Agilent, Santa
Clara, CA, USA), anti-phosphorylated c-Jun (rabbit phospho
S73; Abcam), anti-neurofilament (anti-NF) H, clone SMI32
(mouse, BioLegend, San Diego, CA, USA), anti-NF (mouse,
2H3 clone, Hybridoma Bank, Iowa, IA, USA), anti-Cleaved
Caspase-3 (Asp175; rabbit, Cell Signaling Technology, Danvers,
MA, USA).
Then, the sections were incubated with appropriate
fluorochrome-conjugated secondary antibodies (Alexafluor,
anti-rabbit 647, anti-mouse 488; CyTM3 AffiniPure anti-mouse
and anti-rabbit; Jackson ImmunoResearch Laboratories, West
Grove, PA, USA), mounted on 2% gelatin-coated slices,
coverslipped with the anti-fade mounting medium Mowiol
and analyzed with a Leica TCS SP5 confocal laser scanning
microscope (Leica Microsystems).
For detecting phosphorylated-c-Jun (p-c-Jun) and cleaved
Caspase-3 antibody co-localization, in order to solve the
problem that the two antibodies were made in the same species
(rabbit), p-c-Jun signal was first revealed by using the anti-rabbit
IgG biotinylated secondary antibody (Vector Laboratories,
Burlingame, CA, USA), followed by HRP-streptavidin
incubation (diluted 1:100 in 0.1 M PBS), and the sequential
TSA reactions with FITC-tyramide, 1:100 in its amplification
diluent (TSAr biotin detection kit, PerkinElmer, Waltham, MA,
USA; Stack et al., 2014; Faget and Hnasko, 2015); then cleaved
Caspase-3 signal was detected using the standard protocol for
immunofluorescence described above.
For the analysis of neuromuscular junctions (NMJs), the
muscle slices were incubated for 30 min at room temperature
with the Alexafluor-555-conjugated bungarotoxin (Invitrogen),
diluted in 0.1 M PBS, pH 7.4, 0.5% Triton X-100.
Histochemistry
For Nissl staining, spinal cord sections were mounted on 2%
gelatin-coated slides and air-dried overnight. Sections were then
hydrated in distilled water, immersed in 0.1% Cresyl violet
acetate (Sigma Aldrich) and cover-slipped with Eukitt (Bio-
Optica).
For hematoxylin/eosin (H/E) staining, sections of quadriceps
muscle were stained firstly with hematoxylin, then with
eosin (Bio-Optica), dehydrated in ascending series of ethanol
(95%–100%) and cleared in xylene. The sections were drawn
and analyzed by Neurolucida software (MicroBrightField Inc.,
Williston, VT, USA) and data were obtained by the associated
data analysis software NeuroExplorer (MicroBrightField).
Western Blot
For western blot analysis, five animals for each group were
rapidly killed at age P12 and L1–L4 spinal cord segments
were quickly removed and frozen in liquid nitrogen; they were
mechanically homogenized in a hypotonic buffer containing
a mixture of proteinase and phosphatase inhibitors (Sigma-
Aldrich, St. Louis, MO, USA). Protein concentrations were
quantified using the Bradford Assay (Bio-Rad Protein Assay
500-0006, Munich, Germany). Five grams of TIF extracted
proteins were separated by 10% SDS polyacrylamide gel
electrophoresis. PVDFmembranes were blocked in Tris-buffered
saline (5% non-fat milk powder, 0.1% Tween20, 1 h, room
temperature). Primary antibodies were diluted in the same buffer
(incubation overnight, 4◦C) using: c-Jun (cat. #9165, 1:1,000, Cell
Signaling Technology, Danvers, MA, USA; molecular weights
48 kDa and 43 kDa), p-c-Jun [Ser63] (cat. #9164, 1:1,000,
Cell Signaling Technology, Danvers, MA, USA; molecular
weight 48 kDa), cleaved Caspase-3 (asp175; cat. #9661,
1: 250, Cell Signaling Technology; molecular weights 19 kDa
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and 17 kDa), Actin (1:5,000, Millipore; molecular weight
43 kDa). Blots were developed using horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology)
and the Clarity Western ECL Blotting Substrates (Bio-Rad).
Western blots were quantified by densitometry using ImageLab
6.0 software (software associated to ChemiDoc MP images,
Bio-Rad) and was based on at least three independent
experiments.
Quantitative Analysis
The p-c-Jun positive MNs were quantified by counting the
percentage of p-c-Jun+/SMI32+ double labeled cells on the
total SMI32+ MN cell population, using confocal images (40×
magnification, 1 µm z-step size, 10 µm z-volume, acquisition
speed 100 Hz, format 1024 × 1024 pixels) of the ventral horns
of the lumbar spinal cord. Four animals were analyzed for each
group, four spinal cord slices evaluated for each animal.
For the analysis of astrogliosis in the spinal cord, confocal
images (40× magnification, 1 µm z-step size, 8 µm z-volume,
acquisition speed 100 Hz, format 1024 × 1024 pixels; eight
fields for each animal of the spinal cord ventral horns) of
GFAP-positive cells were converted in black and white images,
then the density of immunopositive profiles was quantified
for the four group of animals (WT PBS/D-JNKI1, SMA
PBS/D-JNKI1; three animals per group).
For the analysis of NFs and NMJ innervation, confocal
stacks (serial sections of 1 µm of thickness to scan the
entire NMJ) were analyzed using IMARIS software (Bitplane):
for each animal, at least 100 NMJs were imaged and
reconstructed in 3D by Imaris software; thus, the number of
NF-positive fibers in contact with each NMJs was evaluated
and counted. NF accumulation in NMJs was evaluated using
Imaris software, by calculating the ratio between NF labeling
area/volume and bungarotoxin (NMJ) labeling area/volume.
NMJ volume was evaluated using Imaris (Bitplane): more
than 100 NMJs were considered for each animal. These
images were used for analysis or assembled into extended-
focus photographs. Brightness, color, and contrast were balanced
and assembled into panels with Inkscape (Free vector graphics
editors).
To morphologically evaluate the quadriceps muscle, in terms
of mean fiber area and Feret’s diameter, the sections were drawn
and analyzed by Neurolucida software (MicroBrightField Inc.,
Williston, VT, USA) and data were obtained by the associated
data analysis software NeuroExplorer (MicroBrightField). More
than 100 fibers were drawn and analyzed for each animal: we then
averaged the means obtained from single animals.
For the MN counting (SMA PBS n = 6; SMA D-JNKI1
n = 6; WT PBS n = 5; WT D-JNKI1 n = 5), Nissl-
stained slices, containing a representative series of the lumbar
spinal cord (L1–L4; 1 sections every 320 µm), were analyzed
using a stereological technique, the Optical Fractionator,
a computer-assisted microscope and the StereoInvestigator
software (MicroBrightField Inc., Williston, VT, USA). MNs were
counted when characterized by an area ≥80 µm2 and located
in a congruent position. The cell density was reported as MN
number/mm3.
Statistical Analysis
The data were evaluated as means ± standard error of mean
(SEM). Statistical analysis was performed using GraphPad
Prism 6.0 software (GraphPad Software, San Diego, CA,
USA).
For the histological and histochemical analyses, we first
tested the value distribution with Kolmogorov-Smirnov and
Shapiro-Wilk tests of normality: then, according to their
gaussian or not-normal distribution, unpaired Student’s t-test or
Wilcoxon-Mann-Whitney test were respectively used, for simple
1:1 comparison (WT PBS vs. SMA PBS, and SMA PBS vs. SMA
D-JNKI1 groups). Additionally, one-way ANOVA was used for
multiple comparisons in case of parametric data.
In the behavioral analysis, the one-way ANOVA for repeated
measures and the Bonferroni post hoc tests were used for
the tail suspension test, the hind-limb suspension test, the
righting reflex and the negative geotaxis test. Moreover, to better
confirm the results, in those tests expressed with not normally
distributed data (i.e., righting reflex and negative geotaxis test)
the contingency table analysis (Fisher exact test) was applied.
The lifespan/survival of SMA PBS and SMA D-JNKI1
animals was analyzed using Kaplan-Meier test. For the body
weight analysis, we used two-way ANOVA repeated measures;
moreover, as suggested by El-Khodor et al. (2008), data were also
represented as a Kaplan-Meier plot, defined as the time from one
initiating event (birth, P0) to a terminating event: the latter one is
considered as the ‘‘the postnatal day when: (1) the animal lagged
in body weight by two standard deviations from the established
normal average body weight gain of the WT controls; and (2) the
body weight remained two standard deviations below the average
on each subsequent days’’ until the last observation (P12; El-
Khodor et al., 2008). Differences were considered significant
when p < 0.05. The analyses were performed blinded for the
genotype and the treatment of the mice.
RESULTS
Analysis of Motor Neuronal and Muscular
Alteration in P12 SMA Mice Compared to
WT Littermates
To shed light on the cell death type ongoing in SMA and
understand the potential role of JNK pathway in the disease
pathogenesis, by WB analysis we first quantified the p-c-Jun
protein fraction (a JNK target) in spinal cords of P12 SMA
and WT pups: we found an increase of about 20% in relative
phosphorylation intensity in SMA group compared to WT
(p = 0.014, Figure 1A), confirming the results of Genabai
et al.’s (2015) group. Moreover, the quantification of cleaved
Caspease3 relative phosphorylation showed an increase of
about 32% in SMA mice (p = 0.003; Figure 1B). Then
we also performed double immunolabeling for p-c-Jun and
SMI32 protein (a specific marker of MNs) to quantify the
percentage of p-c-Jun expressing SMI32-positive MNs in the
ventral horns of the spinal cord. WT animals showed a small
percentage (about 8%) of p-c-Jun activated MNs, indicating
a physiological activation of stress signaling pathways in
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FIGURE 1 | Analysis of c-Jun and active Caspase-3 phosphorylation in WT and spinal muscular atrophy (SMA) pups. (A) Western Blot of the relative phosphorylation
intensity of phosphorylated-c-Jun (p-c-Jun)/c-Jun signal in P12 WT and SMA PBS-treated animal spinal cord. (B) Western Blot of the relative phosphorylation
intensity of active Caspase-3 signal in P12 WT and SMA PBS-treated animal spinal cord. Unprocessed original scans of blots are shown in Supplementary
Figure S1. (C) Confocal images showing p-c-Jun/SMI32-positive cells in the ventral horns of PBS-treated WT and SMA spinal cord. Upper panels show p-c-Jun
positive nuclei (in red), indicated by arrowheads; central panels indicate SMI32-positive motor neurons (MNs; in green). In lower merge panels, the colocalization of
p-c-Jun and SMI32 is displayed and, in addition, cell nuclei are labeled by DAPI staining (in blue): insets show higher magnification of p-c-Jun/SMI32-double labeled
MNs. Scale bar 50 µm. (D) Quantification of the percentage of MNs (SMI32+) expressing p-c-Jun in WT and SMA PBS-treated animals at age P12. ∗P < 0.05;
∗∗P < 0.01; ∗∗∗P < 0.001.
healthy tissue, probably due to postnatal axonal refinement
(Qu et al., 2013; Yuan et al., 2014). On the contrary, SMA
control mice (PBS-treated) showed a significant increase in
p-c-Jun+/SMI32+ expressing cells (39%) compared to WT
(Mann-Whitney test; p = 0.0002; Figures 1C,D). Moreover, we
found that in many MNs, the expression of p-c-jun colocalized
with the expression of cleaved Caspase-3, reinforcing the
hypothesis that thoseMNs with high activation of stress signaling
pathway are in the process of apoptosis (Supplementary
Figure S2).
According to the literature (Branchu et al., 2013; Biondi et al.,
2015; Genabai et al., 2015), these data confirm that JNK-signaling
pathway is activated in SMA MNs and is probably involved in
neuronal cell death. Indeed, confirming previous observations
(d’Errico et al., 2013; Piras et al., 2017), here we report the
reduction in the density of MNs in SMA spinal cord compared
to WT group (WT PBS = 1,651.14 ± 90.3 cells/mm3; SMA
PBS = 891.22 ± 82.5 cells/mm3; Mann-Whitney test, p = 0.0043;
Figures 2A,A′,B). As a consequence of neurodegeneration,
proximal muscles of SMA mice are early affected by atrophy
(Valsecchi et al., 2015; Boido et al., 2018): indeed, quadriceps
fibers showed reduced area (WT PBS = 578.4 ± 80.8 µm2;
SMA PBS = 297.7 ± 31.7 µm2; unpaired t-test, p = 0.043;
Figures 2C,C′,D), perimeter (WT PBS = 90.8 ± 7.1 µm;
SMA PBS = 76.2 ± 1.9 µm; unpaired t-test, p = 0.036;
Figure 2E), maximal (WT PBS = 32.4 ± 1.7 µm; SMA
PBS = 28.04 ± 0.78 µm; unpaired t-test, p < 0.001) and
minimal Feret’s diameter (WT PBS = 22.8 ± 1.4 µm; SMA
PBS = 16.7± 0.85 µm; unpaired t-test, p< 0.001; Figure 2F). As
expected, also the NMJs are strongly affected in SMA, showing
a reduced endplate volume (WT PBS = 335.8 ± 14.2 µm3; SMA
PBS = 175.7± 10.6µm3; unpaired t-test, p< 0.0001; Figure 2G),
together with an increased number of multi-innervated NMJs
(WT PBS = 16.5± 2.3%; SMA PBS = 6± 0.45%; Mann-Whitney
test, p = 0.012) and a decreased number of mono-innervated
NMJs (WT PBS = 91.2 ± 0.4%; SMA PBS = 77.7 ± 2.5%;
Mann-Whitney test, p = 0.013; Figure 2H). By Imaris software,
we also quantified NF accumulation (a hallmark of the disease),
bymeasuring the ratio between the area/volume of NF expression
and the area/volume of the α-bungarotoxin (BTX)-labeled
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FIGURE 2 | Comparison of MN survival and muscular fiber dimension and innervation between WT and SMA mice at P12. (A,A’) Nissl-stained MNs in the ventral
horns of WT and SMA mice spinal cord. Arrowheads indicate MN in the higher magnification insets a,a’. (B) Quantification of MN density between WT and SMA
mice. (C,C’) Hematoxylin/eosin (H/E)-stained representative images showing WT and SMA quadriceps fibers. Insets c,c’ show higher magnification of the muscular
fibers. (D) Analysis of muscle fiber area in WT and SMA mice. (E) Analysis of muscle fiber perimeter in WT and SMA mice. (F) Analysis of maximal and minimal
Feret’s diameter of WT and SMA muscle fibers. (G) Quantification of neuromuscular junction (NMJ) volume. (H) Quantification of the percentage of mono and
multi-innervated NMJs in WT mice and SMA littermates. (I,I’) Double immunostaining against α-bungarotoxin (BTX, in red) and neurofilament (NF, in green) is
employed for analyzing NF accumulation into the plaques in WT and SMA mice. (J) The area of NF accumulation is measured as the ratio between the area of the NF
labeling and the area of the NMJ labeling. (K) The volume of NF accumulation is measured as the ratio between the volume of NF labeling and the volume of NMJ
labeling. Scale bars: 50 µm (A,A’); 40 µm (C,C’); 25 µm (I-I’). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
NMJs: we detected a significant increase of NF area (WT
PBS = 0.55 ± 0.04 µm2; SMA PBS = 0.77 ± 0.03 µm2;
unpaired t-test, p = 0.0004; Figures 2I,I′,J) and volume (WT
PBS = 0.35 ± 0.04 µm2; SMA PBS = 0.61 ± 0.04 µm3; unpaired
t-test, p = 0.0001; Figure 2K) in SMA NMJs compared to WT
littermates.
Overall, these data suggest that JNK-signaling pathway is
activated in SMA, can trigger MN death and consequently
muscular/NMJ defects: therefore, the pharmacological inhibition
of this pathway could lead to the amelioration of the pathology.
D-JNKI1 Administration in WT Mice Does
Not Affect the Correct Murine
Development
Given the importance of JNK as a key molecule in CNS
development (Coffey, 2014), we have first verified that D-JNKI1
administration did not interfere with the physiological MN
development of pups: therefore we treated WT mice, by
administering D-JNKI1 or PBS every 3 days, from P1 to
P10. In the histological analysis of the spinal cord at P12
(day of sacrifice), we found no differences between PBS-
and D-JNKI1-treated WT mice, in terms of MN density
and astrogliosis (p > 0.05). Moreover, in the analysis of
quadriceps, we found neither differences in fiber dimensions
(area, perimeter and Feret’s diameters), nor in NMJ volume
(p > 0.05). Finally, as observed for control PBS-treated,
WT pups treated with D-JNKI1 peptide showed a higher
percentage of mono-innervated NMJs, compared to multi-
and denervated ones, but no difference in NMJ innervation
percentage (p > 0.05). All the results are summarized in
Table 1.
Concerning the behavioral tests, the administration of
D-JNKI1 compound to WT pups seemed to slightly affect the
posture in the first days after birth, as assessed by the tail
suspension test (WT PBS, N = 3; WT D-JNKI1, N = 11; ANOVA
for repeated measures, F(1,12) = 16.40; Bonferroni post hoc test,
p < 0.05 at P2; Figure 3A) and the hind-limb suspension test
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TABLE 1 | Parameters analyzed in the comparison between PBS-treated and
D-JNKI1-treated WT mice at P12.
WT PBS WT D-JNKI1
MN density (mm2) 1651.1 ± 90.3 1589.6 ± 54.4
Astrogliosis (% signal) 1.1 ± 0.2 0.94 ± 0.2
Fiber area (µm2) 570.4 ± 83.7 528.9 ± 52.8
Fiber perimeter (µm) 90.8 ± 7.1 88.7 ± 5.1
Max Feret’s diameter (µm) 33.1 ± 2.7 32.4 ± 1.7
Min Feret’s diameter (µm) 22.9 ± 1.4 22.4 ± 1.4
NMJ volume (µm3) 335.8 ± 14.2 342.7 ± 24.1
% Mono-innervated fibers 91.2 ± 0.4 91.0 ± 0.7
The density of motor neurons (MNs) and the astrogliosis were evaluated in the
ventral horns of WT spinal cord. In the analysis of quadriceps fibers, the fiber area,
fiber perimeter and the Feret’s diameters (max and min) were analyzed. In the
analysis of neuromuscular junctions (NMJs), the volume and the percentage of
mono-innervated junctions were compared in PBS and D-JNKI1 WT groups. No
statistical significant differences are observed between WT PBS and WT D-JNKI1
groups for all the parameters analyzed (p > 0.05).
(WT PBS, N = 3; WT D-JNKI1, N = 11; ANOVA for repeated
measures, F(1,12) = 11.04; Bonferroni post hoc test, p < 0.001 at
P2; Figure 3B). However, such differences were then rapidly
compensated starting from P4. No differences between PBS-
and D-JNKI1-treated WT were observed in the other behavioral
tests (i.e., in the negative geotaxis test and righting reflex,
Figures 3C–D’).
FIGURE 3 | D-JNKI1 treatment partially influences motor performances only in
the early phases of development of WT pups. Tail suspension test (A),
hind-limb suspension test (B), negative geotaxis test (C,C’) and righting reflex
test (D,D’) have been used to evaluate the motor performances of PBS- and
D-JNKI1-treated WT mice. ∗P < 0.05; ∗∗∗P < 0.001.
These data suggest that in WT animals the inhibition of
JNK pathway could partially influence the very early postnatal
development, without serious consequence for the following
phases, the achievement of motor milestones and the correct
MN/muscle/NMJ development.
Reduction of Phospho-c-Jun Expression in
SMA MNs After D-JNKI1 Administration
Based on the described evidence, we decided to administer
D-JNKI1 inhibitor to SMAmice. The treatments were performed
following the same protocol described above for WT pups. At
P12, spinal cord tissue was collected and processed for WB and
immunohistochemical analysis, to evaluate the effect of D-JNKI1
chronic treatment on the p-c-Jun inhibition.
By WB analysis, c-Jun phosphorylation intensity was only
lightly reduced in SMA animals after D-JNKI1 treatment,
compared to SMA PBS (unpaired t-test, p > 0.05, data
not shown). However, to better highlight the efficacy of
D-JNKI1 treatment specifically on MNs, we quantified by
immunohistochemical analysis the percentage of p-c-Jun
expressing SMI32-positive MNs in PBS and D-JNKI1-treated
SMA groups: the percentage of p-c-Jun+/SMI32+ co-labeled cells
was significantly reduced in SMA mice treated with D-JNKI1
peptide (Mann-Whitney test, p = 0.038; Figures 4A,B).
Finally, we also evaluated by WB the expression of cleaved
Caspase-3 in SMA PBS and SMA D-JNKI1: we observed
a significant decrease (about 16%) in apoptotic signal after
D-JNKI1 administration (unpaired t-test, P = 0.0055; Figure 4C),
suggesting that JNK-inhibition can exert a neuroprotective role
in the spinal cord.
D-JNKI1-Administration Extends the
Survival of MNs and Reduces Astrogliosis
in SMA Spinal Cord
To confirm the neuroprotective effect of D-JNKI1, we
stereologically counted lumbar (L1–L4) MNs in treated and
untreated mice. Indeed, one of the major features of SMA
disease is a selective degeneration of lower MNs in the spinal
cord that results in a progressive skeletal muscle denervation,
atrophy and paralysis (Lorson et al., 1999). As expected, D-
JNKI1-administration in SMA mice significantly increased the
density of MNs, compared to PBS-treated SMA pups (SMA PBS,
N = 6; SMA D-JNKI1, N = 6; Mann-Whitney test, p = 0.026;
Figures 5A,B). Thus, these data suggest that the inhibition of
JNK pathway can delay MN death in the spinal cord of SMA
mice.
Moreover, in addition to the MN loss, a remarkable
neuroinflammation is reported in SMA (McGivern et al., 2013;
Rindt et al., 2015; Deguise and Kothary, 2017): therefore, we
evaluated astrogliosis in the spinal cord by the analysis of
GFAP signal in the spinal ventral horns. Results showed that
D-JNKI1 treatment in SMA reduced astrogliosis compared to
SMA controls (SMA PBS, N = 6; SMA D-JNKI1, N = 6;
Mann-Whitney test, p < 0.001; Figures 5C,D). The reduction of
the inflammation observed can be related to the increased MN
survival.
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FIGURE 4 | Positive effect of D-JNKI1 treatment on MN survival in SMA mice,
at P12. (A) Quantification of the percentage of MNs (SMI32+) expressing
p-c-Jun between PBS- and D-JNKI1-treated SMA pups. (B) Confocal images
showing p-c-Jun/SMI32-positive cells in the ventral horns of PBS- and
D-JNKI1 treated SMA mice. Upper panels show p-c-Jun positive nuclei (in
red), indicated by arrowheads; central panels indicate SMI32-positive MNs (in
green). In lower merge panels, the colocalization of p-c-Jun and SMI32 is
displayed and, in addition, cell nuclei are labeled by DAPI staining (in blue):
insets show higher magnification of p-c-Jun/SMI32-double labeled MNs.
(C) Western blot of the relative phosphorylation intensity of cleaved Caspase-3
in SMA-PBS and SMA D-JNKI1 pups. Unprocessed original scans of blots are
shown in Supplementary Figure S1. Scale bar 50 µm. ∗P < 0.05;
∗∗P < 0.01.
D-JNKI1-Treatment Reduces Atrophy of
Quadriceps Muscle in SMA Mice
We have hypothesized that the MN death delay supported
by D-JNKI1 could positively affect also muscular trophism
and innervation. Therefore, we analyzed the morphology of
quadriceps muscles at P12, by H/E staining and morphological
analysis by Neurolucida Software. We evaluated the mean fiber
area, perimeter, and the Feret’s diameter (max) of 100 muscle
fibers per animal: we observed statistically significant differences
for all the evaluated parameters in SMA mice treated with
D-JNKI1, compared with SMA PBS, as reported in Table 2. Thus,
we concluded that the inhibition of JNK pathway in SMA was
able to slow down the atrophy of muscular fibers.
D-JNKI1-Treated SMA Pups Show More
Mature Neuromuscular Junctions
Given that we observed a reduction in MN death and an increase
in muscle fiber size in SMA pups after D-JNKI1 treatment, we
TABLE 2 | Analysis of quadriceps fiber area, perimeter and maximal Feret’s
diameter in PBS-treated and D-JNKI1-treated spinal muscular atrophy (SMA)
mice.
SMA PBS SMA D-JNKI1 t-test
Area (µm2) 297.7 ± 31.7 408.3 ± 23 P = 0.047∗
Perimeter (µm) 64.6 ± 3.4 76.2 ± 1.9 P = 0.040∗
Max Feret’s diameter (µm) 23.4 ± 1.2 28.4 ± 0.8 P = 0.035∗
The measurements and statistical comparisons (t-test) are indicated (∗p < 0.05).
FIGURE 5 | Analysis of MN survival and astrogliosis in the ventral horns of
SMA spinal cord at P12, after D-JNKI1 treatment. (A) Nissl-stained MNs in the
ventral horns showing differences between PBS-treated and D-JNKI1-treated
SMA mice. (B) Quantification of MN density between PBS-treated and
D-JNKI1-treated SMA pups. (C) Representative images showing a reduction
in glial fibrillary acidic protein (GFAP) signal (astrogliosis) between PBS and
D-JNKI1 SMA groups. (D) Quantification of the percentage of astrogliosis, in
terms of GFAP+ signal, in the ventral horns of SMA-PBS and
SMA-D-JNKI1 animals. Scale bars: 50 µm (A); 40 µm (C). ∗P < 0.05;
∗∗∗P < 0.001.
then looked at NMJs and their innervation, to find a possible
improvement in the innervation of hind-limb muscles, after
inhibiting JNK pathway. We first measured NMJ volume using
IMARIS software: results show that D-JNKI1 administration
increased the dimensions of NMJs, compared to PBS-control
SMA pups (SMA PBS, N = 79; SMA D-JNKI1, N = 121; t-test,
p< 0.001; Figures 6A,A′,B,B′,C).
We also evaluated the NMJ innervation, by looking at the
number of NFs contacting the endplate. Indeed, it is known that
during development, the endplates are subject to a remodeling
mechanism, which consists in a selective synapse stabilization
due to a progressive removal of excessive motor axon terminals
on myofibers, going from multiple to single innervation of each
myofiber (Macintosh et al., 2006; Bloch-Gallego, 2015). Thus, the
presence of mono-innervated myofibers indicates a more mature
phenotype of the NMJs, together with a high perforation number
and the increase of NMJ dimensions (Valsecchi et al., 2015; Boido
and Vercelli, 2016). We discriminated among denervated (no
filaments), mono-(contacted by only one NF) and multi-(two or
more filaments) innervated NMJs in SMA. In D-JNKI1-treated
SMA animals we found a significant increase in the percentage
of mono innervated junctions compared to SMA controls (SMA
PBS: 77.7± 2.5%; SMA D-JNKI1: 85.5± 0.87%; Mann-Whitney
test; p = 0.028, Figure 6D), compensated by a decrease in the
percentage of multi-innervated and denervated NMJs, compared
to SMA PBS (Mann-Whitney test; p > 0.05). Thus, D-JNKI1
administration to SMA pups positively led to the acquisition of
a more mature phenotype (mono-innervation) of NMJs.
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FIGURE 6 | Comparison of NMJ dimensions and innervation between
PBS-treated and D-JNKI1 treated SMA mice (A–B’) Images showing NMJ
(BTX in red; Nf in green) dimensions in PBS (A,B) and D-JNKI1-treated (A’,B’)
SMA quadriceps. (C) Analysis of NMJ volume in PBS treated and D-JNKI1
treated SMA groups. (D) Quantification of the percentage of mono-innervated,
multi-innervated and denervated NMJs in SMA PBS and SMA D-JNKI1
groups. Scale bars: 60 µm (A); 20 µm (B). ∗P < 0.05; ∗∗P < 0.01.
Additionally, the NMJs of SMA models and patients display
a massive accumulation of NF in terminal axons, due to
an aberrant cytoskeletal organization of synaptic terminals,
associated with defect of axonal sprouting and reduction of
branched structures of the postsynaptic apparatus (Cifuentes-
Diaz et al., 2002). Using IMARIS software, we found a similar
level of accumulation of NF between SMA PBS and SMA
D-JNKI1 groups (t-test for NF area and volume, p > 0.05, not
shown), thus demonstrating that JNK inhibition has no impact
on the dysregulation of the axonal transport machinery and the
delayed transport of protein components to the axonal terminal.
Therefore, although we observed that the inhibition of JNK
pathway in SMA mice led to a more mature phenotype of NMJs
in terms of innervation (increase in mono-innervation), the
treatment did not induce a reduction in the accumulation of NF.
The Effect of D-JNKI1 Administration on
Motor Behavior and Survival
To investigate whether the reduced neurodegeneration and the
ameliorated muscular trophism/innervation could also improve
motor performance, pups underwent a battery of behavioral
tests from P2 to P12: tail suspension, righting reflex, hind-limb
suspension and negative geotaxis tests. Behavioral assessment
showed that D-JNKI1 administration in SMA mice improved
motor performances in the tail suspension test, the hind-limb
suspension test and the negative geotaxis.
More in detail, the administration of JNK-inhibitor
ameliorated the hind-limb posture in mutant mice, leading
to a higher score both in the tail suspension test (SMA PBS,
N = 12; SMA D-JNKI1, N = 20; ANOVA for repeated measures;
F(1,30) = 17.22, Bonferroni post hoc test, p < 0.0001; Figure 7A)
and the hind-limb suspension test (SMA PBS, N = 12; SMA
D-JNKI1,N = 20; ANOVA for repeated measures; F(1,30) = 59.71,
Bonferroni post hoc test, p < 0.0001; Figure 7B). However, in
the hind-limb suspension test, no differences were observed
regarding the latency to fall (p > 0.05, Figure 7B’). No statistical
significant differences in the ANOVA were also seen in the
righting reflex test between SMA D-JNKI1 and SMA PBS
groups, even if D-JNKI1 treated animals showed a general
improvement in performing this test (Figure 7C), supported by
the contingency table analysis (Fisher exact test at P7, p = 0.04,
Figure 7C’). Conversely, in the negative geotaxis test, SMA
D-JNKI1-treated animals showed a significant increase in the
motor performance compared to SMA PBS, starting from
P10 (SMA PBS, N = 12; SMA D-JNKI1, N = 20; ANOVA for
repeated measures; F(1,30) = 38.20, Bonferroni post hoc test,
p< 0.001 at P10; p< 0.05 at P12; Figure 7D), also confirmed by
the contingency table analysis (Fisher exact test at P10; p = 0.009,
Figure 7D’). Thus, inhibition of JNK pathway in SMA mice
partially improved motor performances, possibly due to the
increased MN survival and, consequently, to the ameliorated
muscular tone and strength.
We also monitored the body weight during the entire
treatment. Compared to WT, the weight of SMA mice reached
a plateau between P8 and P10, then started to decrease until
death (Boido et al., 2018). Administration of D-JNKI1 resulted
in a slight increase in weight compared to PBS-treated SMA
mice (ANOVA for repeated measures. At P12, SMA PBS:
3.29 ± 0.19 g; SMA-D-JNKI1: 3.54 ± 0.14 g, unpaired t-test,
p> 0.05). As suggested by El-Khodor et al. (2008), we converted
the body weight analysis into a Kaplan-Meier plot: we observed
that PBS-treated SMAmice showed a strongly anticipated weight
reduction compared to D-JNKI1-treated group (Kaplan-Meier
curve, Log-rank Mantel test, p < 0.0001), although the latter
ones never reached the WT results (considered as control mice,
Figure 7E).
Finally, in a separate set of experiments, we evaluated the
D-JNKI1 efficacy in extending SMA lifespan. We observed
that the administration of D-JNKI1 significantly increased
the survival of treated mice, compared to PBS-treated SMA
(SMA PBS, N = 20; SMA D-JNKI1, N = 20; Kaplan-
Meier test, Log-rank statistical test, p < 0.05; Figure 7F).
Additionally, the average lifespan was 13.9 ± 0.61 for
PBS SMA and 15.9 ± 0.52 for D-JNKI1-treated SMA
(unpaired t-test, p = 0.02).
DISCUSSION
The Inhibition of JNK Cascade Represents
a Potential Therapy for SMA
SMA is a severe neurodegenerative disease, the most common
in infancy due to genetic causes: the autosomal recessive gene
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FIGURE 7 | D-JNKI1 treatment improves overall state of wellbeing and motor performances in behavioral tests. Tail suspension test (A), hind-limb suspension test
score (B) and time (B’), righting reflex test (C,C’) and negative geotaxis test (D,D’) have been used to evaluate the motor performances of PBS- and
D-JNKI1-treated SMA mice. (E) Event time plot for body weight deviation of PBS SMA. D-JNKI1 SMA and PBS WT (Kaplan-Meier curve, Log-rank Mantel Cox test,
p < 0.05). (F) Kaplan-Meier survival curve shows that D-JNKI1 treatment can significantly extend SMA lifespan (p < 0.05). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
(SMN1) is carried by one person over 35/50. The major
pathological landmark is a selective degeneration of lower MNs,
resulting in progressive skeletal muscle denervation, atrophy and
paralysis (Lorson et al., 1999; Valsecchi et al., 2015). The severity
of the disease is classified into four types (SMA I-IV) based on
SMN2 gene copy number, age of onset and motor function: type
II SMA is considered the intermediate form, characterized by an
early age of onset (7–18 months), reduced lifespan (10–40 years)
and severe loss of muscular tone and strength (D’Amico et al.,
2011).
Despite it is well known that the deletion/mutation in
SMN1 gene is the genetic cause of SMA disease, the molecular
mechanisms leading to MN death are poorly understood.
Recently, it has been demonstrated that the intracellular stress
signaling pathways are selectively activated in presence of low
levels of SMN (Genabai et al., 2015): indeed, the upstream
MAP kinases that mediate the JNK protein activation are
phosphorylated in the spinal cords of SMA II mice and SMA
patients. Moreover, the in vitro inactivation of the JNK3 is able
to reduce the degeneration of SMN-deficient neurons and to
provide neuroprotection (Yamasaki et al., 2012; Genabai et al.,
2015). Additionally, by deleting Jnk3 in the type II SMA pups, the
authors observed a significant reduction of neurodegeneration,
a partial systemic rescue of SMA phenotype, improved motor
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functions, and increased lifespan of SMA mice (Genabai et al.,
2015).
Thus, JNK signaling pathway activation seems to be involved
in MN degeneration, highlighting that this cascade can be
therapeutically targeted (Borsello and Forloni, 2007). For this
reason, we targeted pharmacologically the progression of SMA
disease by taking advantage of a selective cell-penetrating
synthetic peptide inhibitor of all the three JNK isoforms. The
so-called D-JNKI1 peptide has been described as a Tat-Cargo
peptide that prevents the protein-protein interaction between
JNK and its JBD-depended targets by competitive mechanisms,
without interfering with ATP (Bonny et al., 2001; Borsello
et al., 2003a; Repici et al., 2007). D-JNKI1 resulted effective in
the treatment of different pathological conditions. Indeed, in
experimental models of focal cerebral ischemia, the injection
of D-JNKI1 peptide was able to reduce the infarct size by
about the 70%–90%: the treatment was effective both when
administered as late as 12 h after ischemia (Borsello et al., 2003a)
and before the ischemic lesion, in pre-treatment paradigms
(Repici et al., 2007). Similarly, in an experimental model
of epilepsy, D-JNKI1 administration was able to reduce the
number of degenerating neurons in hippocampal CA (Spigolon
et al., 2010) and to prevent ATP release and poly(ADP-
ribose)-polymerase (PARP) cleavage in brain mitochondria
(Zhao et al., 2012). Importantly, D-JNKI1 reverted the cognitive
impairments and LTP defects in AD mouse model as well
(Sclip et al., 2011). Finally, following sciatic nerve transection,
the pharmacological inhibition of all the three JNK isoforms
prevented the onset of neuropathic pain, by reducing the
reactivation of the downstream GAP43 axonal protein after
injury and by inducing a significant analgesic effect (Manassero
et al., 2012).
D-JNKI1 Administration Reduces
Apoptotic Marker Expression in the Spinal
Cord of SMA Mice
Both the activation of JNK and the phosphorylation of c-Jun
protein have been observed in spinal cord MNs from SMA
mice and SMA patients, compared to healthy subjects (Genabai
et al., 2015). Our results confirm such observations, since at P12
c-Jun phosphorylation is higher in type II SMA mice compared
to WT littermates, suggesting the activation of the intracellular
stress signaling pathways. Thus, D-JNKI1 represents a proper
peptide to be tested in SMA mice. Therefore, we chronically
administered JNK inhibitor, by i.p. injection, in type II SMA
pups, starting from age P1 until P10, and we analyzed c-Jun
phosphorylation and cleaved Caspase-3 levels both by WB and
IHC. The dose and timing of D-JNKI1 administration have
been previously tested, and no toxic effects have been found
on cell survival, due to the peptide concentration or to chronic
administration (Repici et al., 2007; Spigolon et al., 2010). Indeed
it has been showed that multiple D-JNKI1 administration show
cumulative neuroprotective effects on cells (Gao et al., 2009;
Manassero et al., 2012); moreover, D-JNKI1 peptide can cross
the BBB with high efficiency in both intact and lesioned CNS
(Borsello et al., 2003b; Repici et al., 2007): since in SMA it
is still debated if BBB is intact (Lorson et al., 2010; Somers
et al., 2016), D-JNKI1 administration can bypass this issue
anyway.
We observed that D-JNKI1 administration can reduce p-c-Jun
levels in SMA spinal cord: this was particularly evident by
IHC analysis, by which we have quantified the number of
p-c-Jun-positive MNs. Our results confirm a strong reduction
of p-c-Jun+/SMI32+ cells after treatment, and provide evidence
of the inhibitory role in vivo of peptide in MNs. Finally, the
protective effect of D-JNKI1 was also demonstrated by the
reduction in cleaved Caspase-3 signal observed in SMA spinal
cord after treatment.
D-JNKI1 Administration Exerts
Neuroprotective Effects and Delays Motor
Performance Worsening in SMA Mice
By quantifying the density of MNs in the spinal cord of
SMA mice, we found that D-JNKI1 treatment is effectively
neuroprotective against MN degeneration. In addition, the
peptide significantly decreased neuroinflammation (in terms of
reduction in astrogliosis) in SMA treated pups compared to SMA
controls. Thus, accordingly to the literature (Genabai et al., 2015),
our data strongly demonstrate that, in SMN deficiency condition,
JNK activation is implied in MN degeneration, and suggest JNK
inhibition as a potential therapeutic approach to reduce neuronal
death in spinal cord.
In case of SMA, the consequence of the degeneration of
spinal cord MNs is a progressive relentless muscular atrophy
that leads to premature death due to respiratory failure (Lorson
et al., 2010; Govoni et al., 2018). Thus, to evaluate whether
the induced neuroprotection correlated to an increase muscular
trophism, we then looked at the quadriceps, a muscle early
affected by the disease. By analyzing the fibers, indeed, we found
differences between D-JNKI1- and PBS-treated SMA pups, with
a significant increase of muscle fiber size (in terms of mean
fiber area and perimeter) in D-JNKI1-treated animals. Moreover,
the evaluation of Feret’s diameters (which are highly suggested
parameters to determine the size of muscle fibers; Dubache-
Powell, 2008; Boido et al., 2018) confirms such differences,
highlighting that the increased survival of MNs after D-JNKI1
administration leads to a reduction of muscular atrophy.
Increasing evidence in the last years suggest that the NMJs
of SMA animal models and SMA patients are also altered,
showing a delayed development. Indeed, several alterations have
been described in SMA NMJs, including immature phenotype,
reduced perforation number, small dimension, and remarkable
fragmentation (Cifuentes-Diaz et al., 2002; Kariya et al., 2008;
Kong et al., 2009; Valsecchi et al., 2015; Boido and Vercelli, 2016;
Boido et al., 2018). Thus, we analyzed if the neuroprotective
effect of D-JNKI1 could also affect NMJ development. We
found that JNK inhibition results in a partial endplate rescue
with improved NMJ size and innervation. Indeed, the increase
in mono-innervated NMJs after D-JNKI1 treatment (with the
resulting decrease in multi-innervated and denervated NMJs)
suggests a more mature NMJ phenotype, that, in turn, might
influence the muscle trophism (Ling et al., 2012). Therefore, the
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inhibition of JNK signaling pathway represents a valid target
to partially rescue SMA phenotype by supporting the crosstalk
between MNs and muscles, as already demonstrated in the
inhibition of ROCK pathway (Bowerman et al., 2010, 2012;
Genabai et al., 2015).
Moreover, SMA NMJs show a pathological accumulation
of NF that is associated to a slower and delayed transport of
protein components, important for the endplate maintenance
and functionality (Murray et al., 2008; Torres-Benito et al.,
2012; Boido and Vercelli, 2016). Although we found an
improvement in the NMJ innervation, this does not correlate
with a reduction in NF accumulation in treated SMA mice.
Indeed, we observed only a slight reduction in D-JNKI1-treated
SMA NF volume compared to PBS-treated littermates. The
causes of NF accumulation are still poorly understood (Dale
and Garcia, 2012), although shared by several neurodegenerative
diseases, such as Alzheimer’s disease (Yang et al., 2009)
amyotrophic lateral sclerosis (Brady, 1993) and symmetrical
sensory polyneuropathy (Fernyhough et al., 1999). Interestingly,
it seems that the increase in phosphorylation of NF subunits is
concomitant with the increase in phosphorylation of JNK1/2
(Fernyhough et al., 1999; Yang et al., 2009), suggesting
the hyperphosphorylation and accumulation of NF as a
JNK1/2 dependent mechanism. Therefore, we expected
a significant reduction of NF in D-JNKI1-treated SMA
mice that inexplicably did not occur. As known, SMN
deficiency affects the splicing machinery activity, probably
determining alterations also in the microtubule-based motor
proteins and other interacting proteins, and justifying the
altered cellular trafficking and NF accumulation: due the
complexity of the mechanisms involved and intertwined, it
is possible that D-JNKI1 is not able to completely rescue the
axonal trafficking defects observed in SMA (Ikenaka et al.,
2012).
However, overall, we proved the D-JNKI1 efficacy not only
histologically (at spinal and (neuro) muscular level), but also
behaviorally: we found that the inhibition of JNK signaling
pathway delayed the worsening of motor behavior, in particular
in the tail suspension, the hind-limb suspension and the negative
geotaxis test. Moreover, we found that D-JNKI1 administration
on SMA pups delays the progressive weight loss, compared to
SMA control littermates. Finally, JNK inhibition increased SMA
mice lifespan of about 2 days, that can be considered a significant
increase related to the short SMA mice lifespan (about 14 days).
Nevertheless, seen the impressive histological/molecular results
we obtained, we expected an even higher lifespan increase:
however, the SMA pathogenesis is very complex and surely other
pathways leading to MN death are implicated and can trigger the
neurodegeneration (as for example the autophagic pathway or
the crosstalk between Rho and ERK kinases, whose dysfunctions
are well documented in SMA; Hensel et al., 2017, and Piras and
Boido, 2018, respectively).
Concluding Remarks
Although a definite cure for SMA is still missing, in the last years,
the researchers focused their attention on both SMN-dependent
and independent approaches, which have shown promising
results in order to find effective therapeutic strategies (Govoni
et al., 2018).
To stimulate the protein synthesis of SMN2 gene by
enhancing transcription, many SMN-dependent approaches
have been developed (Lorson et al., 2010; Howell et al.,
2014; Maharshi and Hasan, 2017; Mendell et al., 2017;
Talbot and Tizzano, 2017; Tosolini and Sleigh, 2017), also by
modulating activators/inhibitors of different signaling pathways
(e.g., ERK/ELK-1 and AKT/CREB, Biondi et al., 2010; Branchu
et al., 2013; STAT5/prolactin, Farooq et al., 2011, NF-κB,
Arumugam et al., 2018). SMN-independent approaches are also
able to partially rescue SMA phenotype, targeting different
pathways (as autophagy, Piras et al., 2017) or proteins, like ROCK
(Bowerman et al., 2010, 2012), Plastin3 (Oprea et al., 2008) and
the zinc finger protein ZPR1 (Ahmad et al., 2016). Moreover,
some therapeutic strategies are aimed at ameliorating SMA
phenotype by acting on endplates and improving neuromuscular
transmission (Wyatt and Keirstead, 2010; Wadman et al., 2012;
Nishimune et al., 2014; Boido et al., 2018; Lai et al., 2018).
Among the others, to counteract the progressive
neurodegeneration, the inhibition of the apoptotic cascade
seemed particularly interesting: indeed, the genetic inhibition of
Jnk3 in SMAmice resulted in the partial restore of the phenotype
without affecting the levels of SMN in the nervous system and
muscles (Genabai et al., 2015). Here we demonstrated that the
pharmacological inhibition of all the three isoforms of JNK
proteins is useful for reducing neurodegeneration in SMA mice,
without showing side effects (i.e., evident physical or psychical
discomforts, premature death, interference with the MN
development mechanisms. . .). Our results support the previous
findings on Jnk genetic inhibition in SMA mice by Genabai et al.
(2015), representing an implementation of their results, in the
perspective of translational pharmacological approaches. Indeed,
we found that the use of D-JNKI1 successfully results in a partial
systemic rescue of the SMA phenotype, by reducing MN death,
delaying motor function worsening, and improving muscle fiber
thickness, NMJ size and innervation.
Overall, our results suggest that the deficit of SMN and JNK
activation could be intertwined. It is known that in neurons
JNK signaling is a Janus-faced pathway and can play a dual
role, by mediating either physiological or pathological responses
(Coffey et al., 2000). Indeed, on one side JNK can regulate
neuronal activity by inducing phosphorylation of microtubule-
associated proteins, leading to microtubule stability in neurite
formation (Xu et al., 2011; Coffey, 2014); on the other, JNK is also
involved in stress-induced apoptosis (Kuan et al., 1999; Tournier
et al., 2001; Coffey et al., 2002), playing a critical role during
injury responses associated with neurodegeneration (Xu et al.,
2011; Genabai et al., 2015). Moreover, JNK may cooperate with
other signaling pathways to generate context and site-specific
responses (Lamb et al., 2003; Xu et al., 2011).
As concerns SMA, it is likely that the decrease in SMN level
leads to cellular stress, resulting in JNK pathway phosphorylation
and contributing to MN death, as proposed by Genabai et al.
(2015): they reported the activation of the MAP3K proteins
ASK1 and MEKK1 in the spinal cord of SMA patients and
mice, suggesting that at least two possible signaling pathways
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can be involved in JNK activation. Indeed, they observed a
marked increase in the activation of the MAP2K protein MKK4
(known to be activated by ASK1) compared to other MAP2Ks
(i.e., MKK7), suggesting a specificity for the activation of the
pathways downstream to JNK (Genabai et al., 2015). Moreover,
in neurons, low levels of SMN may result in free pools of
protein Gemin5—a part of SMN complex—which in turns
may increase the phosphorylation levels of ASK1/MKK4/JNK
scaffold complex. In addition, the protein complex composed by
MEKK1/MKK7/JNK may be activated by the specific neuronal
protein JIP3 (Genabai et al., 2015; Ahmad et al., 2016).
Thus, by D-JNKI1, that blocks the JIP-JNK interaction,
both pathways might be affected. Further studies will elucidate
whether a specific pathway is preferentially involved in SMA
progression, in order to exploit it for more focused therapies.
Moreover, given that SMA can be considered as a multi-
systemic disease (Shababi et al., 2014; Simone et al., 2016), we
can hypothesize that the inhibition of all the JNK isoforms could
exert protective effects also in other body district affected in SMA
pathology, such as the heart (Bevan et al., 2010; Heier et al., 2010),
the diaphragm (Supinski et al., 2009) and other skeletal muscles
(Anderson et al., 2003), in which it has been shown that this
family protein is expressed.
Finally, our treatment could represent an effective potential
adjuvant to other therapies, like Nusinersen (ISIS 396443),
an antisense oligonucleotide (ASO) already used in phase
3 clinical studies to increase the production of full-length
SMN2 protein (Adams, 2017; Maharshi and Hasan, 2017), or
AVXS-101, an AAV-based treatment to restore SMN protein
expression (Mendell et al., 2017). Indeed, the use of ASOs or
gene therapy represents a very promising strategy for SMA,
as demonstrated by the improvement of motor functions and
extended survival observed inmouse models and human patients
(Parente and Corti, 2018). However such approaches have
some important limitations: (i) they are merely SMN-dependent
strategies and, despite their remarkable efficacy, they are
not completely effective in arresting the disease progression,
probably because other molecular pathways contributing to SMA
pathogenesis are overlooked; (ii) they may require repeated
lumbar punctures (Nusinersen) that, in case of scoliosis or
vertebral fixation surgery, can represent a hard challenge for
a prolonged application; (iii) their cost is extremely expensive
(for Nusinersen, the expense can reach $750,000 in the first
year and approximately $375,000/year subsequently; Goyal and
Narayanaswami, 2018); and (iv) the majority of trials have strict
eligibility criteria, determining the exclusion of milder patients.
For all these reasons, therapies targeting other molecular
pathways are strongly required, in order to assure an effective
treatment to all the SMA patients. Indeed, by delaying the MN
death, D-JNKI1, eventually in combination with ASOs and gene
therapy, could increase their SMN-dependent effects, since such
therapies start when the symptoms are already present and
therefore the cell death pathway already triggered.
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